Bluestem Capital
Bluestem Capital is a Sioux Falls, South Dakota-based private equity firm founded in 1989 that provides recapitalization, buyout, and growth-equity capital to roughly 15 mid-market companies in healthcare, medtech, ophthalmology, and real estate, favoring hands-on partnerships with aligned management teams.
- Company typePrivate
- Founded1989
- HeadquartersSioux Falls, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Bluestem Capital does
Bluestem Capital Company, LLC is a Midwest-based private equity firm headquartered at 101 S Phillips Ave, Ste 501 in Sioux Falls, South Dakota, founded in 1989. The firm operates with 1–10 employees — a stable five-partner group led by founding partner Steve Kirby alongside partners Tyler J. Stowater (joined 2000), Sandy Horst (joined 1998, CFO), Nikole Mulder (joined September 2002), and Jon Kirby. Bluestem pursues recapitalizations, buyouts, and mezzanine-style growth equity, targeting growth-stage companies with proven products, market barriers to entry, and management teams with substantial personal financial investment. Its portfolio spans roughly 15 named companies concentrated in healthcare, medical devices, ophthalmology, biotech, real estate, and select consumer/tech — including Sydnexis (pediatric myopia drug SYD-101), Virtual Incision (MIRA miniaturized robotic surgery system), Orasis Pharmaceuticals (Qlosi presbyopia eye drops), Shoulder Innovations (shoulder replacement implants, IPO'd NYSE July 2025), Zerigo Health (NB-UVB phototherapy), Newton (contoured prism lenses), POET (ethanol/biorefining), and Continental Realty Group. The firm deliberately favors face-to-face deal sourcing, "win-win" alignment structures, and co-investment with healthcare-specialist VCs such as RA Capital, Longitude Capital, Visionary Ventures, Arboretum Ventures, and Johnson & Johnson Innovation. Revenue derives from equity returns on portfolio exits — realized through the 2025 Shoulder Innovations IPO, FDA authorizations (MIRA, Feb 2024), EU approval of SYD-101 (June 2025), and ongoing commercialization — rather than disclosed management fees, and the firm operates an AppFolio investor portal for LP reporting.
Bluestem Capital firmographics
Firmographics- Name
- Bluestem Capital
- Legal name
- Bluestem Capital Company, LLC
- Website
- https://bluestemcapital.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bluestem Capital is a Sioux Falls, South Dakota-based private equity firm founded in 1989 that provides recapitalization, buyout, and growth-equity capital to roughly 15 mid-market companies in healthcare, medtech, ophthalmology, and real estate, favoring hands-on partnerships with aligned management teams.
- Ownership category
- akta.pro rank
Bluestem Capital industry classification
Industry- Product category
- Private Equity
- NAICS
- Other Financial Investment Activities (5239)
- SIC
- Investors, Nec (6799)
- akta.pro primary industry
- Business Services (B2B) Growth Equity (FSANACAD)
- akta.pro secondary industry
- SME Term Loans & Growth Capital (FSAKAGAB)
Keywords
Where Bluestem Capital is headquartered
LocationHeadquarters
- HQ city
- Sioux Falls
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bluestem Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Private Equity Returns: Bluestem Capital generates returns through equity investments in portfolio companies, expecting financial returns when those companies succeed or exit through acquisition, IPO, or other liquidity events.
Go-to-market motion2 records
Marketing channels4 records
Bluestem Capital product offering
Product offeringCore offering
Bluestem Capital is a Midwest-based private equity firm that provides growth capital, recapitalization, buyout financing, and mezzanine financing to companies with proven products, strong management teams with substantial financial investment, and market barriers to entry. The firm invests across healthcare, medical technology, biotechnology, real estate, and consumer sectors, focusing on win-win structures that align entrepreneur and investor interests.
Product overview
Bluestem Capital is a Midwest-based private equity firm that invests in portfolio companies across various industries including healthcare, medical technology, biotechnology, real estate, and consumer products. Rather than offering its own unified product platform, Bluestem provides investment and growth capital to companies developing distinct products and services. Key portfolio companies include Zerigo Health (chronic skin condition treatment), Orasis Pharmaceuticals (Qlosi eye drops), Virtual Incision Corporation (MIRA Surgical System), Sydnexis (SYD-101 myopia treatment), Newton (eyecare lenses), Shoulder Innovations (shoulder implants), and others spanning ophthalmology, medtech, biopharmaceuticals, real estate, and nutraceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- Private Equity Investment (Growth Capital)
Quantifiable outcome
- Successful portfolio company exits and IPOs (e.g., Shoulder Innovations IPO on NYSE July 2025)
- +1 more outcomes
Companies that use Bluestem Capital
Customer profileNamed customers15 records
Segments3 records
Ideal customer profiles1 record
Bluestem Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bluestem Capital partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Santen Pharmaceutical Co., Ltd.coreSanten licensed rights from Sydnexis to commercialize SYD-101 as Ryjunea in Europe, Middle East, and Africa. Santen is a Japan-based company specialized in eye health operating in 60+ countries.
- HCA Florida Mercy HospitalminorFirst hospital in Southeast U.S. to perform hysterectomy using MIRA Surgical System (Virtual Incision). Part of FDA-approved clinical study under IDE.
- Hoag (Newport Beach, California)minorFirst hospital in Western U.S. to offer MIRA Surgical System through MIRA First Access Program. National leader in robotic-assisted surgery with 30,000+ procedures completed. Designated Center of Excellence in Robotic Surgery (COERS).
- Sovato HealthcorePartner with Virtual Incision for remote robotic-assisted surgery capabilities. Sovato provides the world's only comprehensive solution for enabling remote surgery and procedure programs.
- City of Hope National Medical CenterminorTop 5 cancer center (U.S. News & World Report) collaborated on remote robotic surgery demonstration with Virtual Incision and Sovato. Surgeons included Dr. Yuman Fong, Dr. Yanghee Woo, Dr. Yasmin Zerhouni, Dr. Clayton Lau.
- University of Illinois ChicagominorCollaborated on remote robotic surgery demonstration with Virtual Incision. Dr. Francesco Maria Bianco performed remote procedures.
- Optus PharmaceuticalsminorExclusive licensing agreement with Orasis Pharmaceuticals for commercialization of Qlosi in Korea. $18M in milestone payments plus double-digit royalties.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Bluestem Capital competitors and assessment
Company assessmentDirect peers
- Sterling Investment Partners: Lower middle-market private equity firm providing growth equity and control capital to consumer, business services, and healthcare companies. Comparable to Bluestem in scale, sector mix, and growth-equity orientation.
- NewSpring Capital: Middle-market private equity firm investing growth equity and controlling stakes across healthcare, tech, and business services. Closely comparable to Bluestem's diversified growth-equity model and stage orientation.
- Linden Capital Partners: Healthcare-focused middle-market private equity firm based in Chicago, investing across healthcare services, medtech, and life sciences. Highly comparable to Bluestem in healthcare sector emphasis and Midwest base.
- Varsity Healthcare Partners: Healthcare-focused lower middle-market private equity firm investing growth capital into healthcare services, devices, and technology companies. Matches Bluestem's healthcare focus and growth-stage orientation.
- GTCR: Chicago-based private equity firm investing in growth-stage companies across healthcare, technology, and business services via minority and control structures. Closely comparable to Bluestem's growth-equity playbook, though at materially larger scale.
- Bison Capital: Lower middle-market private equity firm focused on growth equity investments in founder-led businesses. Directly comparable investment model (minority growth equity, alignment-driven structures) to Bluestem.
- Ampersand Capital Partners: Boston-area private equity firm specializing in healthcare and life sciences growth and buyout investments. Comparable to Bluestem's healthcare portfolio weighting and growth-stage investment orientation.
- Five Points Capital: Lower middle-market private equity firm making control and minority growth investments in healthcare, business services, and specialty industries. Comparable to Bluestem's stage, size, and sector breadth.
- Insight Equity: Middle-market private equity firm focused on control investments and operational improvement across diversified industries. Comparable to Bluestem's lower-middle-market, operationally engaged approach.
Broad incumbents
- Madison Dearborn Partners: Chicago-based private equity firm investing across healthcare, financial services, tech, and consumer via buyouts and growth investments. Compares to Bluestem in geography and sector breadth, but at substantially larger AUM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Bluestem Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bluestem Capital leadership team
Management profileNumber of profiles
Profiles4 records
Bluestem Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bluestem Capital M&A and investment
M&A and investmentM&A
Investments29 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bluestem Capital
What does Bluestem Capital do?
Bluestem Capital is a Midwest-based private equity firm that provides growth capital, recapitalization, buyout financing, and mezzanine financing to companies with proven products, strong management teams with substantial financial investment, and market barriers to entry. The firm invests across healthcare, medical technology, biotechnology, real estate, and consumer sectors, focusing on win-win structures that align entrepreneur and investor interests.
Is Bluestem Capital a public or private company?
Bluestem Capital is a private company. It is classified as management employee owned and is currently operating.
When was Bluestem Capital founded?
Bluestem Capital was founded in 1989. It employs 1 to 10 people.
Where is Bluestem Capital based?
Bluestem Capital is headquartered in Sioux Falls, United States, in the North America region.
How does Bluestem Capital make money?
One revenue line is on record: private Equity Returns.
Who are Bluestem Capital's main competitors?
Direct peers on record are Sterling Investment Partners, NewSpring Capital, Linden Capital Partners, Varsity Healthcare Partners, GTCR, Bison Capital, Ampersand Capital Partners, Five Points Capital and Insight Equity. Madison Dearborn Partners is listed as a broad incumbent.
Does Bluestem Capital have an API?
No public API is recorded for Bluestem Capital.
What industry is Bluestem Capital in?
Bluestem Capital's product category is Private Equity. Its primary akta.pro industry code is FSANACAD, Business Services (B2B) Growth Equity, with a secondary code of FSAKAGAB, SME Term Loans & Growth Capital. Its NAICS code is 5239 and its SIC code is 6799.